Brain Health, Reimagined

At Gate Neurosciences, we believe there’s a better way to treat central nervous system (CNS) diseases. By overcoming the limitations of current and emerging treatments, we offer a new generation of safe, potent, and rapid acting-therapies for the nearly 1 billion people worldwide suffering from neuropsychiatric and cognitive disorders.

Directly Enhancing Synaptic Function

Synaptic dysfunction is the biological basis for a number of CNS disorders, including depression. Our next-generation therapeutic candidates are designed to restore healthy and balanced brain signaling by enhancing underlying synaptic function using a novel, direct mechanism that modulates the NMDA receptor without causing the dissociative effects seen in other emerging therapies.

Microscope with molecules

Powered by Precision

Our precision development approach includes objective EEG biomarkers, targeted patient subpopulations, and robust translational modeling combined with clinical trial experience in thousands of patients to position our therapeutic candidates for long-term success.

Pipeline

Our lead program, zelquistinel, is a novel oral NMDAR PAM that has demonstrated a differentiated, well-tolerated safety profile and statistically significant rapid-acting antidepressant effects in a Phase 2a study in Major Depressive Disorder.

pipeline *Next Phase 2 study to be initiated in 2023.

CNS Is In Our DNA

Our team has devoted decades to researching CNS disease biology and improving the treatment of CNS disorders, giving us the deep expertise necessary for meaningful innovation.

Leadership

  • Michael G. McCully

    Michael G. McCully

    President & CEO

  • Ronald M. Burch M.D

    Ronald M. Burch, M.D., Ph.D.

    Chief Medical Officer

  • Anantha Shekar M.D Image

    Anantha Shekhar, M.D., Ph.D.,

    Chief Scientific Officer

See All Leadership

Board of directors

  • Michael G. McCully

    Michael G. McCully

    Director, CEO

  • Derek A. Small

    Derek A. Small

    Executive Chairman

  • Sarah J. Schlesinger, M.D.

    Sarah J. Schlesinger, M.D.

    Director

Investors and Key Shareholders

News and Events

01/24/2024

Gate Neurosciences Announces Clinical Collaboration with Beacon Biosignals to Advance Precision EEG Biomarkers in Major Depressive Disorder

11/07/2023

Gate Neurosciences Announces Positive Topline Human EEG Biomarker Results Demonstrating Dose-Dependent Target Activation in Phase 1 Study of Apimostinel

09/14/2023

Gate Neurosciences Takes on Depression with Event-Driven Pharmacology

Contact Us

Headquarters

1210 Waterway Blvd
Indianapolis, IN 46202
United States